1. Home
  2. UDMY vs GLUE Comparison

UDMY vs GLUE Comparison

Compare UDMY & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Udemy Inc.

UDMY

Udemy Inc.

HOLD

Current Price

$5.80

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$16.48

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UDMY
GLUE
Founded
2009
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
UDMY
GLUE
Price
$5.80
$16.48
Analyst Decision
Buy
Buy
Analyst Count
9
2
Target Price
$9.00
$19.50
AVG Volume (30 Days)
4.1M
1.2M
Earning Date
02-12-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.25
Revenue
$795,801,000.00
$181,538,000.00
Revenue This Year
$2.34
$81.52
Revenue Next Year
$2.54
N/A
P/E Ratio
N/A
$64.14
Revenue Growth
2.53
1112.27
52 Week Low
$4.86
$3.50
52 Week High
$10.61
$19.17

Technical Indicators

Market Signals
Indicator
UDMY
GLUE
Relative Strength Index (RSI) 56.44 54.50
Support Level $5.80 $14.97
Resistance Level $7.16 $19.17
Average True Range (ATR) 0.32 1.24
MACD 0.10 -0.30
Stochastic Oscillator 34.95 41.28

Price Performance

Historical Comparison
UDMY
GLUE

About UDMY Udemy Inc.

Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: